Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

06.01.20

EyeGate Pharma to Present at Jefferies 2020 Virtual Healthcare Conference

WALTHAM, MA, June 1, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
05.06.20

EyeGate Pharma Reports First Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, May 6, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
03.31.20

EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study

WALTHAM, MA, March 31, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
03.04.20

EyeGate Pharma Reports Full Year 2019 Financial Results and Provides Business Update

WALTHAM, MA, March 4, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
01.06.20

EyeGate Pharma Completes Enrollment in Follow-on PE Pilot Study

WALTHAM, MA, January 6, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
01.03.20

EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

WALTHAM, MA, January 3, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today...
Read more
12.31.19

EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

WALTHAM, MA, December 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today...
Read more
12.17.19

EyeGate Pharma Receives $1.9 Million From Exercised Warrants

WALTHAM, MA, December 17, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today that it has received approximately $1.9 million from the exercise of warrants...
Read more